Individuals
Business
Individuals
Business

Lymphoma - Hodgkin lymphoma

The PBS subsidises brentuximab vedotin and pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma.

Patient eligibility

Treatment with brentuximab vedotin and pembrolizumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under  the National Health Act 1953, Section 100 – Efficient funding of chemotherapy for a patient with relapsed or refractory Hodgkin lymphoma and who has failed autologous stem cell transplant (ASCT) or is ASCT naïve.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines restrictions for prescribing brentuximab vedotin and pembrolizumab.

Section 100 arrangements

These items are only available to a patient who is attending:

  • an approved private hospital
  • a public participating hospital, or
  • a public hospital

These items are not PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Applications

Initial treatment

Brentuximab – ASCT failure

Make all initial applications for authority approval to prescribe brentuximab vedotin for the treatment of post-ASCT relapsed or refractory Hodgkin lymphoma in writing and:

All applications must include the completed:

Brentuximab – ASCT naïve

Make all initial applications for authority approval to prescribe brentuximab vedotin for the treatment of ASCT naïve relapsed or refractory Hodgkin lymphoma in writing and:

All applications must include the completed:

Pembrolizumab

Make all initial applications for authority approval to prescribe pembrolizumab for the treatment of relapsed or refractory Hodgkin lymphoma in writing and:

All applications must include the completed:

Continuing treatment

To make continuing applications for treatment with brentuximab vedotin and pembrolizumab call the PBS Complex Drugs Programs enquiry line.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 May 2018